28 May 2023
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine" or the "Company")
Notice of Results, Investor
Presentation, and AGM
Ondine Biomedical Inc. (AIM: OBI) announces that it will publish its audited results for the
year ended 31 December 2023 ("Full Year Results") and Annual Report
2023 on 7 June 2024. Dr. Nicolas Loebel, President and Chief
Technology Officer of the Company, will provide a live presentation
relating to the Full Year Results via Investor Meet Company on 10
June 2024, 16:30 BST (08:30 Pacific time).
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9 June
2024, 09:00 BST (01:00 Pacific time), or at any time during the
live presentation.
Investors can sign up to Investor
Meet Company for free and add to meet ONDINE BIOMEDICAL INC.
via:
https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor
Investors who already follow ONDINE
BIOMEDICAL INC. on the Investor Meet Company platform will
automatically be invited.
A full overview of the 2023 fiscal
year will be presented in the Annual Report 2023, which will be
available on the Company's website on 7 June 2024. at:
www.ondinebio.com/investors/reports-documentation/.
The slides and recording of the live presentation will be posted to
the same webpage as soon as available following the presentation,
no later than 11 June 2024.
The Company's 2024 Annual General
Meeting is being held virtually on 28 June 2024 at
16:00 BST (08:00 Pacific time); registered shareholders and their
duly appointed proxyholders can attend the Meeting online via the
link being provided in the Notice of Meeting.
|
Ondine Biomedical
Inc.
|
|
|
Angelika Vance, Corporate Communications
|
+001 (1) 604 838 2702
|
|
|
|
|
Singer Capital
Markets (Nominated Adviser and Joint Broker)
|
|
|
Aubrey Powell, Sam
Butcher
|
+44 (0)20 7496 3000
|
|
|
|
|
RBC Capital Markets
(Joint Broker)
|
|
|
Rupert Walford, Kathryn Deegan
|
+44 (0) 20 7653 4000
|
|
|
|
|
Vane Percy &
Roberts (Media Contact)
|
|
|
Simon Vane Percy, Amanda Bernard
|
+44 (0) 77 1000 5910
|
About Ondine Biomedical
Inc.
Ondine Biomedical Inc. is a Canadian
headquartered company innovating in the field of photodisinfection
therapies. Ondine has a pipeline of investigational products, based
on its proprietary photodisinfection platform, in various stages of
development. Ondine's nasal
photodisinfection technology is approved in several jurisdictions
under the brand name Steriwave ™. It has been awarded the CE mark
and, in the US, has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA. Products
beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns and other
indications.